KR102823567B1 - Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법 - Google Patents

Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법 Download PDF

Info

Publication number
KR102823567B1
KR102823567B1 KR1020217023828A KR20217023828A KR102823567B1 KR 102823567 B1 KR102823567 B1 KR 102823567B1 KR 1020217023828 A KR1020217023828 A KR 1020217023828A KR 20217023828 A KR20217023828 A KR 20217023828A KR 102823567 B1 KR102823567 B1 KR 102823567B1
Authority
KR
South Korea
Prior art keywords
carcinoma
cancer
alkyl
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217023828A
Other languages
English (en)
Korean (ko)
Other versions
KR20220051301A (ko
Inventor
제논 디. 콘테아티스
밍종 리
새뮤얼 케이. 레즈닉
즈후아 수이
Original Assignee
르 라보레또레 쎄르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르
Priority to KR1020257020196A priority Critical patent/KR20250093588A/ko
Publication of KR20220051301A publication Critical patent/KR20220051301A/ko
Application granted granted Critical
Publication of KR102823567B1 publication Critical patent/KR102823567B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020217023828A 2018-12-27 2019-12-27 Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법 Active KR102823567B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257020196A KR20250093588A (ko) 2018-12-27 2019-12-27 Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785519P 2018-12-27 2018-12-27
US62/785,519 2018-12-27
PCT/US2019/068652 WO2020139991A1 (en) 2018-12-27 2019-12-27 Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257020196A Division KR20250093588A (ko) 2018-12-27 2019-12-27 Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법

Publications (2)

Publication Number Publication Date
KR20220051301A KR20220051301A (ko) 2022-04-26
KR102823567B1 true KR102823567B1 (ko) 2025-06-20

Family

ID=69400625

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217023828A Active KR102823567B1 (ko) 2018-12-27 2019-12-27 Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법
KR1020257020196A Pending KR20250093588A (ko) 2018-12-27 2019-12-27 Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257020196A Pending KR20250093588A (ko) 2018-12-27 2019-12-27 Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법

Country Status (38)

Country Link
US (2) US12077534B2 (https=)
EP (1) EP3902803B1 (https=)
JP (3) JP7418441B2 (https=)
KR (2) KR102823567B1 (https=)
CN (1) CN113454085B (https=)
AR (1) AR117544A1 (https=)
AU (1) AU2019416349B2 (https=)
CA (1) CA3124952C (https=)
CL (1) CL2021001721A1 (https=)
CO (1) CO2021009879A2 (https=)
CR (1) CR20210410A (https=)
DK (1) DK3902803T3 (https=)
EA (1) EA202191801A1 (https=)
ES (1) ES2942310T3 (https=)
FI (1) FI3902803T3 (https=)
GE (2) GEP20237519B (https=)
HR (1) HRP20230161T1 (https=)
HU (1) HUE061834T2 (https=)
IL (1) IL284326B2 (https=)
JO (1) JOP20210172B1 (https=)
LT (1) LT3902803T (https=)
MA (1) MA54608B1 (https=)
MD (1) MD3902803T2 (https=)
MX (1) MX2021007829A (https=)
MY (1) MY206578A (https=)
PE (1) PE20212090A1 (https=)
PH (1) PH12021551490A1 (https=)
PL (1) PL3902803T3 (https=)
PT (1) PT3902803T (https=)
RS (1) RS64135B1 (https=)
SA (1) SA521422405B1 (https=)
SG (1) SG11202106637SA (https=)
SI (1) SI3902803T1 (https=)
SM (1) SMT202300109T1 (https=)
TW (1) TWI816962B (https=)
UA (1) UA127525C2 (https=)
WO (1) WO2020139991A1 (https=)
ZA (1) ZA202104423B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
WO2022026892A1 (en) 2020-07-31 2022-02-03 Tango Therapeutics, Inc. Piperidin-1- yl-n-pyrydi ne-3-yl-2-oxoacet am ide derivatives useful for the treatment of mtap-deficient and/or mt a-accumulating cancers
CN115960098B (zh) * 2020-09-11 2026-04-10 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
US20240124454A1 (en) * 2020-12-31 2024-04-18 Nanjing Zaiming Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
DE102021102487A1 (de) * 2021-02-03 2022-08-04 Aixinno Limited Verfahren zum Handhaben biologischer Zellkulturen
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
CN117412967A (zh) * 2021-06-02 2024-01-16 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a抑制剂
AR127404A1 (es) 2021-10-20 2024-01-17 Insilico Medicine Ip Ltd Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos
KR20240148320A (ko) * 2021-12-17 2024-10-11 탱고 테라퓨틱스, 인크. N-(6-아미노-5-메틸피리딘-3-일)-2-(벤조[d]티아졸-5-일)-5-메틸피페리딘-1-일)-2-옥소아세트아마이드의결정질 형태, 약제학적 조성물 및 이의 사용 방법
CN118414338A (zh) * 2021-12-21 2024-07-30 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
WO2023169554A1 (zh) * 2022-03-11 2023-09-14 赛诺哈勃药业(成都)有限公司 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用
JP2025521737A (ja) 2022-06-27 2025-07-10 石▲薬▼集▲團▼中奇制▲薬▼技▲術▼(石家庄)有限公司 三環式化合物およびその使用
CN117430596A (zh) * 2022-07-13 2024-01-23 上海海和药物研究开发股份有限公司 二并环类mat2a抑制剂及其用途
AU2023361063A1 (en) 2022-10-13 2025-04-17 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
CN121241050A (zh) * 2023-03-06 2025-12-30 甘李药业股份有限公司 一种甲硫氨酸腺苷转移酶2a抑制剂及其医药用途
CN121586715A (zh) * 2023-06-14 2026-02-27 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法
WO2025166215A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166260A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166274A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025166257A1 (en) 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509113A (ja) 2000-09-15 2004-03-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2018045071A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2019191470A1 (en) 2018-03-30 2019-10-03 Agios Pharmaceuticals, Inc. Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
CA2420286A1 (en) 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
CN110015962B (zh) 2011-01-28 2022-03-15 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
US20160115164A1 (en) 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
UA125970C2 (uk) 2017-05-22 2022-07-20 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
EA202191800A1 (ru) * 2018-12-27 2021-09-13 Ле Лаборатуар Сервье Сас Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
SG11202112952SA (en) * 2019-05-31 2021-12-30 Servier Lab Heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509113A (ja) 2000-09-15 2004-03-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
WO2018045071A1 (en) 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
WO2019191470A1 (en) 2018-03-30 2019-10-03 Agios Pharmaceuticals, Inc. Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
JP2021519783A (ja) 2018-03-30 2021-08-12 アジオス ファーマシューティカルズ, インコーポレイテッド Mat2aの複素二環式阻害剤、およびがんの治療のための使用方法

Also Published As

Publication number Publication date
SI3902803T1 (sl) 2023-06-30
JOP20210172A1 (ar) 2023-01-30
MX2021007829A (es) 2021-10-26
ZA202104423B (en) 2023-12-20
TW202039490A (zh) 2020-11-01
SMT202300109T1 (it) 2023-05-12
EA202191801A1 (ru) 2021-11-09
EP3902803A1 (en) 2021-11-03
US12077534B2 (en) 2024-09-03
IL284326A (en) 2021-08-31
CN113454085B (zh) 2024-05-07
CA3124952C (en) 2024-07-02
JOP20210172B1 (ar) 2024-12-22
KR20220051301A (ko) 2022-04-26
CL2021001721A1 (es) 2022-02-18
JP2024015340A (ja) 2024-02-01
JP7418441B2 (ja) 2024-01-19
JP2025133887A (ja) 2025-09-11
RS64135B1 (sr) 2023-05-31
BR112021012595A2 (pt) 2021-09-08
AU2019416349B2 (en) 2023-09-28
AU2019416349A1 (en) 2021-07-15
WO2020139991A1 (en) 2020-07-02
JP2022516883A (ja) 2022-03-03
FI3902803T3 (fi) 2023-04-25
CR20210410A (es) 2021-12-08
IL284326B2 (en) 2024-08-01
PH12021551490A1 (en) 2022-04-11
AR117544A1 (es) 2021-08-11
PL3902803T3 (pl) 2023-05-22
MA54608A (fr) 2022-04-06
GEAP202315703A (en) 2023-02-27
UA127525C2 (uk) 2023-09-20
ES2942310T3 (es) 2023-05-31
HRP20230161T1 (hr) 2023-04-28
US20220144820A1 (en) 2022-05-12
TWI816962B (zh) 2023-10-01
HUE061834T2 (hu) 2023-08-28
CA3124952A1 (en) 2020-07-02
PE20212090A1 (es) 2021-11-04
CN113454085A (zh) 2021-09-28
SG11202106637SA (en) 2021-07-29
CO2021009879A2 (es) 2021-10-29
PT3902803T (pt) 2023-04-28
LT3902803T (lt) 2023-04-25
US20250214988A1 (en) 2025-07-03
MA54608B1 (fr) 2023-02-28
NZ777391A (en) 2025-08-29
KR20250093588A (ko) 2025-06-24
DK3902803T3 (da) 2023-02-13
MD3902803T2 (ro) 2023-10-31
EP3902803B1 (en) 2023-02-01
SA521422405B1 (ar) 2024-04-28
IL284326B1 (en) 2024-04-01
MY206578A (en) 2024-12-24
GEP20237519B (en) 2023-07-10

Similar Documents

Publication Publication Date Title
KR102823567B1 (ko) Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법
KR102736073B1 (ko) Mat2A의 헤테로바이시클릭 억제제 및 암 치료를 위한 이의 사용 방법
KR20220050832A (ko) Mat2A의 AZA-헤테로이환 억제제 및 암 치료를 위한 사용 방법
EP3976611A1 (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
RU2809987C2 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
HK40061678A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
HK40061678B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
BR112021012595B1 (pt) Inibidores aza-heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
OA20638A (en) Aza-heterobicyclic inhibitors Of MAT2A and methods of use for treating cancer.
EA046111B1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
HK40062089A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210727

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220810

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240705

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250325

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250617

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250617

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250618

End annual number: 3

Start annual number: 1

PG1601 Publication of registration